Without Tests, Heart Drug May Not Work

Warning on Anti-Clotting Drugs is Largely Ignored

Heart Patient Daniel Siegel: He was never tested to see if his genetics might thwart his anticlotting medicine.
courtesy of daniel siegel
Heart Patient Daniel Siegel: He was never tested to see if his genetics might thwart his anticlotting medicine.

By Elie Dolgin

Published August 15, 2012, issue of August 17, 2012.
  • Print
  • Share Share
  • Single Page

After his heart attack last December, Rabbi Daniel Siegel had two stents implanted in his blocked coronary arteries, and he started on a course of drugs to prevent further clots from forming.

It was Siegel’s second heart attack in a little over five years, and each time his doctors prescribed him the same anti-clotting medicine: Plavix, known generically as clopidogrel.

Yet Siegel’s doctors did not do one thing that drug regulators and scientific experts strongly advocate. They did not also order a genetic test that could have predicted whether Siegel would actually benefit from Plavix’s blood-thinning action.

“No one has ever talked about that,” says Siegel, a resident of Hornby Island, British Columbia, and the director of spiritual resources for ALEPH: Alliance for Jewish Renewal, an international organization based in Philadelphia.

Kaiser Permanente

Siegel’s Canadian doctors are not alone. On the U.S. side of the border, only around one in every 200 physicians actually considers DNA data when prescribing Plavix, according to research from Medco Health Solutions, a healthcare company headquartered in Franklin Lakes, N.J. This low uptake of genetic testing remains despite the fact that in 2010 the Food and Drug Administration added a “black box” warning to Plavix’s prescribing information that noted the link between certain genetic traits and reduced drug response. Such “poor metabolizers,” the FDA said, “may remain at risk for heart attack, stroke, and cardiovascular death.”

The FDA came to that conclusion after considering the results of numerous clinical trials involving thousands of heart patients, which collectively showed that having a reduced-function gene variant dramatically increases the risk of stent thrombosis and other complications. Yet, despite the wealth of medical data, adoption rates of the tests remain low.

“If you look in the literature, the evidence base is compelling,” says Dr. Alan Shuldiner, associate dean for personalized and genomic medicine at the University of Maryland School of Medicine. “The challenge really has been to take these discoveries and move them into the clinic.”

The gene underlying Plavix metabolism is known as CYP2C19. This gene encodes a liver enzyme that helps convert Plavix into its active form to have a full effect. Around 20% of North American Caucasians harbor genetic mutations in this gene that render them less capable of metabolizing Plavix. For these people, doctors often prescribe other antiplatelet agents, such as prasugrel, that don’t rely on CYP2C19 status yet cost more and have higher rates of complications.

The Jewish Daily Forward welcomes reader comments in order to promote thoughtful discussion on issues of importance to the Jewish community. In the interest of maintaining a civil forum, The Jewish Daily Forwardrequires that all commenters be appropriately respectful toward our writers, other commenters and the subjects of the articles. Vigorous debate and reasoned critique are welcome; name-calling and personal invective are not. While we generally do not seek to edit or actively moderate comments, our spam filter prevents most links and certain key words from being posted and The Jewish Daily Forward reserves the right to remove comments for any reason.

Find us on Facebook!
  • What does the Israel-Hamas war look like through Haredi eyes?
  • Was Israel really shocked to find there are networks of tunnels under Gaza?
  • “Going to Berlin, I had a sense of something waiting there for me. I was searching for something and felt I could unlock it by walking the streets where my grandfather walked and where my father grew up.”
  • How can 3 contradictory theories of Yiddish co-exist? Share this with Yiddish lovers!
  • "We must answer truthfully: Has a drop of all this bloodshed really helped bring us to a better place?”
  • "There are two roads. We have repeatedly taken the one more traveled, and that has made all the difference." Dahlia Scheindlin looks at the roots of Israel's conflict with Gaza.
  • Shalom, Cooperstown! Cooperstown Jewish mayor Jeff Katz and Jeff Idelson, director of the National Baseball Hall of Fame, work together to oversee induction weekend.
  • A boost for morale, if not morals.
  • Mixed marriages in Israel are tough in times of peace. So, how do you maintain a family bubble in the midst of war? http://jd.fo/f4VeG
  • Despite the escalating violence in Israel, more and more Jews are leaving their homes in Alaska to make aliyah: http://jd.fo/g4SIa
  • The Workmen's Circle is hosting New York’s first Jewish street fair on Sunday. Bring on the nouveau deli!
  • Novelist Sayed Kashua finds it hard to write about the heartbreak of Gaza from the plush confines of Debra Winger's Manhattan pad. Tough to argue with that, whichever side of the conflict you are on.
  • "I’ve never bought illegal drugs, but I imagine a small-time drug deal to feel a bit like buying hummus underground in Brooklyn."
  • We try to show things that get less exposed to the public here. We don’t look to document things that are nice or that people would like. We don’t try to show this place as a beautiful place.”
  • A new Gallup poll shows that only 25% of Americans under 35 support the war in #Gaza. Does this statistic worry you?
  • from-cache

Would you like to receive updates about new stories?

We will not share your e-mail address or other personal information.

Already subscribed? Manage your subscription.